tetra bio-pharma investor presentation
TRANSCRIPT
OCTOBER 2016
ForewordlookingStatements
Thispresentationcontainscertainforward-lookingstatementsthatmayinvolveanumberofrisksanduncertainties.ActualeventsorresultscoulddiffermateriallyfromtheexpectationsandprojectionsofArcScanInc..TheinformationcontainedinthispresentationhasnotbeenapprovedordisapprovedbyanySecuritiesCommissioninCanada,TheSecuritiesandExchangeCommissionintheUSorotherregulatorybody.ExceptforstatementsofhistoricalfactrelatingtotheCompany,certaininformationcontainedhereinconstitutes"forward-lookingstatements".Forward-lookingstatementsarefrequentlycharacterizedbywordssuchas"plan","expect","project","intend","believe","anticipate"andothersimilarwords,orstatementsthatcertaineventsorconditions"may"or"will"occur.
Forward-lookingstatementsarebasedontheopinionsandestimatesofmanagementatthedatethestatementsaremade,andaresubjecttoavarietyofrisksanduncertaintiesandotherfactorsthatcouldcauseactualeventsorresultstodiffermateriallyfromthoseprojectedintheforward-lookingstatements.ThesefactorsincludetheinherentrisksinvolvedinthedevelopmentofbotanicalbasedpharmaceuticalsormedicaldevicesregulatedbyHealthCanada,theFDAorotherinternationalregulatoryagencies,productobsolescence,theuncertaintiesinvolvedinpatentdefenseandcomplexitiesandtimelinesassociatedwithproductapprovalsinmultiplejurisdictions.
Thepossibilityofprojectcostoverrunsorunanticipatedcostsandexpenses,uncertaintiesrelatingtotheavailabilityandcostsoffinancingneededinthefutureandotherfactors.Circumstancesormanagement'sestimatesoropinionscouldchange.Thereaderiscautionednottoplaceunduerelianceonforward-lookingstatements.Exceptasrequiredbylaw,weundertakenoobligationtoupdateorrevisepubliclyanyforward-lookingstatements,whetherasaresultofnewinformation,futureeventorotherwise,afterthedateonwhichthestatementsaremadeortoreflecttheoccurrenceofunanticipatedevents.Neitherwenoranyofourrepresentativesmakeanyrepresentationorwarranty,expressorimplied,astotheaccuracy,sufficiencyorcompletenessoftheinformationinthispresentation.Neitherwenoranyofourrepresentativesshallhaveanyliabilitywhatsoever,undercontract,tort,trustorotherwise,toyouoranypersonresultingfromtheuseoftheinformationinthispresentationbyyouoranyofyourrepresentativesorfromomissionsfromtheinformationinthispresentation.
InnovationsinthePharmaseuticalizationandNeutraseuticalizationofMedicalCannabis
REPORT:TheCannabisBiotech/PharmaMarketCouldSurpass$20Billionby2020ViridianCapitalAdvisors|Wednesday,02December201505:43 (EST)
THEPHARMACEUTICALAPPROACHTOCANNABISRESEARCHANDMEDICALINNOVATION
APhysician’sdecisiontoprescribeanewdrugorevenanaturalhealthproducthastobebasedonEvidence-BasedMedicine– Alegalandethicalrequirement.
§ Currently,nobodyofevidenceexiststonotsupporttheprescriptionorrecommendationofmedicalmarijuanainanymedicalcondition,includingterminalcancer.AccordingtoCanadianandUSAdrugregulatoryagencies,theisnoevidencetosupportthesafetyandefficacyofmarijuanaforuseinthetreatmentofpainoranyotherindication.
§ TBPproductdevelopmentplanwouldprovidethedatanecessaryfordrugregulatoryagenciestograntmarketingapprovalandphysicianstoprescribeorrecommendourproducts.
§ Ascannabisbecomeslegalisedacrosstheglobethemedicalandscientificcommunitywouldstillrequirepharmaceuticalconsumerdrugproductsdevelopedwithproperresearch,dataandprotocol.InsurancecompanieswillonlybeabletocoverthecostofproductswithDrugIdentificationNumbers.
§ TBPtakesthenaturalaspectsofmedicalcannabisandappliesthescienceofpharmatodevelopproductsthatpatientswant,doctorswanttoprescribeandinsurancecompanieswillcover.
TBPProductPipelineTBPinvestssignificanttimeandcapitalintoacontinuousandsustainablepipelineofproductsbasedonpatientneedsanddrivenbyscientificRandD
PrescriptionDrugs
§ PPP001*:§ bringing‘smoked’marijuanatopatients.
§ PPP002:§ Insomniaacomorbidityinchronicpainpatients.§ Botanicaldrugtoincreasequalitysleepinpatientssufferingfromchronicpain.
§ PPP003*:§ Combinationproduct– oraladministration.§ Chronicpain,PTSDandotherneurologicandpsychiatricconditions.§ CompeteagainstGWwithproprietaryextracts.
§ PTGR*:§ Topicalprescriptiondrugforpainmanagement.
§ R&D*§ togeneratepipeline(createIPanddisease-specifictreatments).
*cannabissativabasedproducts.
24MonthProjectedMilestones
Partners
AlgorithmePharmaisconductingstage1clinicaltrialsofPP001incollaborationwithPhytoPainPharma
McGillUniversityiscollaboratingwithAgrotekandGrowProsonanNSERCfundedresearchstudytodevelopconsumerproductscontainingcannabinoids.
AphriaisapublicallytradedproducerofMedicinalCannabisunderlicensefromtheCanadianFederalGovernment.AphriahaspartneredwithPPPfortheproductionofCannabisforuseinPP001.
TheNationalSciencesandEngineeringResearchCouncilofCanadaconnectsindustrywithworld-firstsinknowledgeandthepeoplebehindthem,fuelingR&Dandleadingtofirstsinthemarketplace.TheyhavegrantedTBPsubsidiaryGrowProsCannabiswithresearchfundingrelatedtothedevelopmentofConsumerproductsincollaborationwiththeuniversityofMcGill.
NaturalHealthProductStrategy
§ Alongwithmedicinalandrecreationalcannabis,naturalhealthproductscontainingnonpsychoactivecannabinoidssuchasCannibidiol(CBD)arewidelygainingpopularityparticularlyintheUnitedStateswheremorefavorableCBDregulationsexist.
§ AgroTekintendstoacquireformulationsandestablishedbrandswiththegoalofintegratingourCannabisR&DintothelessregulatedNHPmarket
Theestimatedsizeofthe2015hempCBDbasedpersonalcareproducts($147million).Thismarksanestimated10%increaseover2014,
anddoesn’tevenincludesalesdatafrombigboxretailers,whichcouldmorethandoubletheestimate.*
*MMJ.com
OvertheCounterNHPPipeLine§ AGT001*:
§ Topicalproductforpainmanagement.
§ AGT002productline-oral*:§ Cardiovasculardiseaseprevention,
athleticperformance,andwell-being.
§ AGT003productline*:§ Topicalproductsforskincare.
§ AGT004*:§ Topicalforwomen- qualityoflife.
§ R&D*:§ CreateIPandpipelineforsupplement
healthcaremarket.
*cannabissativabasedproducts(mayormaynotcontainpsychoactiveingredients)TargetingbothCanadaandUSAsupplement(OTC)markets.
Cannabis/MedicinalPlantcultivationandsourcing
• OriginallyappliedforACMPRlicenseinNovemberof2014,Currentlyinstage3/5
• Ownsaleaseoptionon190acresofagriculturalland45minnorthofOttawa
• Signedaco-opagreementwithDelta9Biotechtocollaborateonlicensingofthefacility
• CurrentlyexaminingalternativelicensingoptionsforPharmaDevelopmentandsourcinglegalsupplyforuseinPharmaandNHPproducts
CurrentMarketValuation~13MValue Total
CommonShares 82.61MWarrantsexp09/28/18 .07-.15 20.7MCompensationWarrants .05 1.5MOPTIONSexp11/5/17 .05-.32 6.3MAveragePriceofWarrants: $0.11AveragePriceofOptions: $0.05
TotalProceedsfromWarrantsandoptions$2.224M
CapitalStructure(asofOct5,2016)
CompetitiveLandscapeGWPharma$GWPHMarketCapitalization:$3.33BUSDGWPharmahas2productsinitspipelineinstage1andstage3forepilepsyandMS.
CannabisScienceInc.$CBISMarketCapitalization$47.22MUSDConductsqualitativeresearchonmedicinalcannabisinanonpharmaceuticalmanor.TheyhavenoproductsinClinicalTesting
INSYSTherapeuticsinc- $INSYMarketCapitalization$810.5MUSDIsatraditionalPharmacompanythatwasawardedorgandrugstatusforCBDfortreatmentofGBM.Theydonothaveanycurrentclinicaltrials
ZynerbaPharmaceuticals$ZYNE-MarketCapitalization$101MUSDDevelopingasyntheticTHCtransdermalpatchaswellasasyntheticCBDgel
CaraTherapeuticsInc.$CARAMarketCapitalization$214.2MR&DonCannabinoidpreceptors.Utilizingsyntheticcompounds
Financing
• Jan15- Oct16Raised~$1.4Mthroughprivateplacementsandexecutedwarrantsat.025-.05-.10-.15
• October2016Secured2MequitylineofCreditfromNYCprivateequityfirmAluminaPartners
• November2016Closeda$914,000financingroundat.15withafull12monthwarrantat.20
Leadership
Operations
• AndreRancourt – ChiefExecutiveOfficer• GuyChamberland,PHD– ChiefScientificofficer• SabinoDiPaola – ChiefFinancialofficer• RyanBrown – VPbusinessdevelopmentandcommunications• RandyRinguette,PHD–MedicalResearcher• CharlesCampbell,PHD–MedicalResearcher
BoardofDirectors
• AndreAudet – Chairman/Director• AndreRancourt – Director• BenoitChotard – Director• RobertBrouilette – Director
